Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology

WY Gao, FS Han, C Storm, W Egan and YC Cheng

Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510.

Phosphorothioate oligodeoxycytidine (S-dCn) was used as a model compound to examine the impact of the number of phosphorothioate linkages and their position on the inhibition of human DNA polymerases and RNase H in vitro. S-dCn with a chain length longer than 15 could inhibit human DNA polymerases and RNase H activities, in a linkage number-dependent manner. Longer oligomers were more potent inhibitors than shorter ones. Kinetic studies indicated that S-dC28 was a competitive inhibitor of DNA polymerase alpha and beta with respect to the DNA template, whereas it was a noncompetitive inhibitor of polymerases gamma and delta. S-dC28 was also a competitive inhibitor of RNase H1 and H2 with respect to RNA-DNA duplex. Susceptibility of these enzymes to inhibition by S-dC28 was in the order of delta approximately gamma greater than alpha greater than beta and RNase H1 greater than RNase H2. Structural-activity relationships were explored with a group of S-dC28 analogs that have phosphorothioate internucleotide linkages at various positions. The inhibitory effect depended on the total number of thioate linkages, rather than the position of the linkages within the oligomer or the chain length itself. No sequence specificity was found. In the presence of the complementary RNA, antisense phosphorothioates (S-oligos) exerted a biphasic effect on RNase H activity. At low concentrations S-oligos could enhance the cleavage of the RNA portion of S-oligo-RNA duplex, whereas at high concentrations (in excess of the complementary RNA) S-oligos could inhibit RNase H and protect the complementary RNA from degradation. Together, these results suggest that the non-sequence-specific inhibitory effect of S-oligos should be taken into consideration in designing antisense inhibitors. This inhibitory activity could be avoided by decreasing the number of phosphorothioate linkages at the backbone, and S-oligos of 15-20 residues are preferable in antisense molecule design.

Volume 41, Issue 2, pp. 223-229, 02/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				R. Bhindi, R. G. Fahmy, H. C. Lowe, C. N. Chesterman, C. R. Dass, M. J. Cairns, E. G. Saravolac, L.-Q. Sun, and L. M. Khachigian Brothers in Arms: DNA Enzymes, Short Interfering RNA, and the Emerging Wave of Small-Molecule Nucleic Acid-Based Gene-Silencing Strategies Am. J. Pathol., October 1, 2007; 171(4): 1079 - 1088. [Abstract] [Full Text] [PDF]

				T. Kuwasaki, M. Hatta, H. Takeuchi, and H. Takaku Inhibition of human immunodeficiency virus 1 replication in vitro by a self-stabilized oligonucleotide with 2'-O-methyl-guanosine-uridine quadruplex motifs J. Antimicrob. Chemother., April 1, 2003; 51(4): 813 - 819. [Abstract] [Full Text] [PDF]

				V. J. Dzau Transcription Factor Decoy Circ. Res., June 28, 2002; 90(12): 1234 - 1236. [Full Text] [PDF]

				J. D. Ahn, R. Morishita, Y. Kaneda, S.-J. Lee, K.-Y. Kwon, S.-Y. Choi, K.-U. Lee, J.-Y. Park, I.-J. Moon, J.-G. Park, et al. Inhibitory Effects of Novel AP-1 Decoy Oligodeoxynucleotides on Vascular Smooth Muscle Cell Proliferation In Vitro and Neointimal Formation In Vivo Circ. Res., June 28, 2002; 90(12): 1325 - 1332. [Abstract] [Full Text] [PDF]

				R. Crinelli, M. Bianchi, L. Gentilini, and M. Magnani Design and characterization of decoy oligonucleotides containing locked nucleic acids Nucleic Acids Res., June 1, 2002; 30(11): 2435 - 2443. [Abstract] [Full Text] [PDF]

				B. Verbeure, E. Lescrinier, J. Wang, and P. Herdewijn RNase H mediated cleavage of RNA by cyclohexene nucleic acid (CeNA) Nucleic Acids Res., December 15, 2001; 29(24): 4941 - 4947. [Abstract] [Full Text] [PDF]

				H. Zhao, T. Laitala-Leinonen, V. Parikka, and H. K. Vaananen Downregulation of Small GTPase Rab7 Impairs Osteoclast Polarization and Bone Resorption J. Biol. Chem., October 12, 2001; 276(42): 39295 - 39302. [Abstract] [Full Text] [PDF]

				A. Wang, P. K. M. Cheung, H. Zhang, C. M. Carthy, L. Bohunek, J. E. Wilson, B. M. McManus, and D. Yang Specific Inhibition of Coxsackievirus B3 Translation and Replication by Phosphorothioate Antisense Oligodeoxynucleotides Antimicrob. Agents Chemother., April 1, 2001; 45(4): 1043 - 1052. [Abstract] [Full Text]

				H J N Andreyev, P J Ross, D Cunningham, and P A Clarke Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma Gut, February 1, 2001; 48(2): 230 - 237. [Abstract] [Full Text] [PDF]

				K.-Y. Jen and A. M. Gewirtz Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies Stem Cells, September 1, 2000; 18(5): 307 - 319. [Abstract] [Full Text]

				D. Li and J. L. Mehta Antisense to LOX-1 Inhibits Oxidized LDL-Mediated Upregulation of Monocyte Chemoattractant Protein-1 and Monocyte Adhesion to Human Coronary Artery Endothelial Cells Circulation, June 27, 2000; 101(25): 2889 - 2895. [Abstract] [Full Text] [PDF]

				V. Prasad, S. Hashim, A. Mukhopadhyay, S. K. Basu, and R. P. Roy Oligonucleotides Tethered to a Short Polyguanylic Acid Stretch Are Targeted to Macrophages: Enhanced Antiviral Activity of a Vesicular Stomatitis Virus-Specific Antisense Oligonucleotide Antimicrob. Agents Chemother., November 1, 1999; 43(11): 2689 - 2696. [Abstract] [Full Text]

				M. Gleave, A. Tolcher, H. Miyake, C. Nelson, B. Brown, E. Beraldi, and J. Goldie Progression to Androgen Independence Is Delayed by Adjuvant Treatment with Antisense Bcl-2 Oligodeoxynucleotides after Castration in the LNCaP Prostate Tumor Model Clin. Cancer Res., October 1, 1999; 5(10): 2891 - 2898. [Abstract] [Full Text] [PDF]

				H. Miyake, A. Tolcher, and M. E. Gleave Antisense Bcl-2 Oligodeoxynucleotides Inhibit Progression to Androgen-Independence after Castration in the Shionogi Tumor Model Cancer Res., August 1, 1999; 59(16): 4030 - 4034. [Abstract] [Full Text] [PDF]

				M. K. Slodzinski and M. P. Blaustein Na+/Ca2+ exchange in neonatal rat heart cells: antisense inhibition and protein half-life Am J Physiol Cell Physiol, August 1, 1998; 275(2): C459 - C467. [Abstract] [Full Text] [PDF]

				A. M. Gewirtz, D. L. Sokol, and M. Z. Ratajczak Nucleic Acid Therapeutics: State of the Art and Future Prospects Blood, August 1, 1998; 92(3): 712 - 736. [Full Text] [PDF]

				V. Balasubramanian, L. T. Nguyen, S. V. Balasubramanian, and M. Ramanathan Interferon-gamma -Inhibitory Oligodeoxynucleotides Alter the Conformation of Interferon-gamma Mol. Pharmacol., May 1, 1998; 53(5): 926 - 932. [Abstract] [Full Text]

				M. Hangai, H. Tanihara, Y. Honda, and Y. Kaneda In Vivo Delivery of Phosphorothioate Oligonucleotides Into Murine Retina Arch Ophthalmol, March 1, 1998; 116(3): 342 - 348. [Abstract] [Full Text] [PDF]

				A. Bierhaus, T. Illmer, M. Kasper, T. Luther, P. Quehenberger, H. Tritschler, P. Wahl, R. Ziegler, M. Muller, and P. P. Nawroth Advanced Glycation End Product (AGE)–Mediated Induction of Tissue Factor in Cultured Endothelial Cells Is Dependent on RAGE Circulation, October 7, 1997; 96(7): 2262 - 2271. [Abstract] [Full Text]

				N. Galeotti, C. Ghelardini, L. Papucci, S. Capaccioli, A. Quattrone, and A. Bartolini An Antisense Oligonucleotide on the Mouse Shaker-like Potassium Channel Kv1.1 Gene Prevents Antinociception Induced by Morphine and Baclofen J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 941 - 949. [Abstract] [Full Text]

				F. I. Raynaud, R. M. Orr, P. M. Goddard, H. A. Lacey, H. Lancashire, I. R. Judson, T. Beck, B. Bryan, and F. E. Cotter Pharmacokinetics of G3139, a Phosphorothioate Oligodeoxynucleotide Antisense to bcl-2, after Intravenous Administration or Continuous Subcutaneous Infusion to Mice J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 420 - 427. [Abstract] [Full Text]

				S. Agrawal, Z. Jiang, Q. Zhao, D. Shaw, Q. Cai, A. Roskey, L. Channavajjala, C. Saxinger, and R. Zhang Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies PNAS, March 18, 1997; 94(6): 2620 - 2625. [Abstract] [Full Text] [PDF]

				M. F. Taylor, J. D. Paulauskis, D. D. Weller, and L. Kobzik In Vitro Efficacy of Morpholino-modified Antisense Oligomers Directed against Tumor Necrosis Factor-alpha mRNA J. Biol. Chem., July 19, 1996; 271(29): 17445 - 17452. [Abstract] [Full Text] [PDF]

				B. P. Monia, J. F. Johnston, H. Sasmor, and L. L. Cummins Nuclease Resistance and Antisense Activity of Modified Oligonucleotides Targeted to Ha-ras J. Biol. Chem., June 14, 1996; 271(24): 14533 - 14540. [Abstract] [Full Text] [PDF]

				M. R. Bennett and S. M. Schwartz Antisense Therapy for Angioplasty Restenosis : Some Critical Considerations Circulation, October 1, 1995; 92(7): 1981 - 1993. [Full Text]

				S. M. Fennewald and R. F. Rando Inhibition of High Affinity Basic Fibroblast Growth Factor Binding by Oligonucleotides J. Biol. Chem., September 15, 1995; 270(37): 21718 - 21721. [Abstract] [Full Text] [PDF]

				R. F. Rando, J. Ojwang, A. Elbaggari, G. R. Reyes, R. Tinder, M. S. McGrath, and M. E. Hogan Suppression of Human Immunodeficiency Virus Type 1 Activity in Vitro by Oligonucleotides Which Form Intramolecular Tetrads J. Biol. Chem., January 27, 1995; 270(4): 1754 - 1760. [Abstract] [Full Text] [PDF]

				C. Stein and Y. Cheng Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science, August 20, 1993; 261(5124): 1004 - 1012. [Abstract] [PDF]